m hs

 a

Here’s a summary of the journal report you’re citing:

Study Overview

The article “Substantially Reduced Life Expectancy in Patients With Hidradenitis Suppurativa: a Finnish nationwide registry study” (H. Tiri, J. Jokelainen, M. Timonen, et al.; British Journal of Dermatology, 2019) analysed life expectancy and causes of death in people with hidradenitis suppurativa (HS) using nationwide health registry data from Finland. (OUP Academic)

Key Findings

• This was a retrospective, registry‑based case–control study comparing individuals diagnosed with HS to two control groups (patients with psoriasis and patients with benign melanocytic naevi). (OUP Academic)

• The investigators used the Finnish Care Register for Health Care to identify cases diagnosed with HS between 1987 and 2014, and obtained death dates and causes from national mortality data through the end of 2015. (OUP Academic)

Life Expectancy Results

• Mean age at death for individuals with HS was substantially lower than in the control groups. On average:

  • HS group: ~60.5 years

  • Psoriasis controls: ~71.1 years

  • Melanocytic naevi controls: ~75.2 years
    This represents a difference of roughly 10–15 years shorter life expectancy in the HS group compared with controls. (Ovid)

Causes of Increased Mortality

While the study itself was brief (a Letter to the editor), further detailed analysis based on the same dataset indicates that:

• Cardiovascular diseases were the most common cause of death in people with HS, with elevated risk relative to controls.

• Neoplasms (cancers) were the second most common cause.

• The shorter lifespan in HS is thought to relate to chronic systemic inflammation and associated comorbidities (e.g., cardiovascular disease, metabolic syndrome), which are highly prevalent in HS. (Oulu University Publication Archive)

Context and Interpretation

• This finding supports broader evidence that HS is more than a skin disorder — it’s a systemic inflammatory condition with elevated risks of serious comorbidities that can impact mortality.

• Other population studies have also found increased all‑cause mortality and specifically elevated cardiovascular mortality in HS patients, though not always adjusted fully for lifestyle factors like smoking and obesity. (pubmed.ncbi.nlm.nih.gov)

If you’d like, I can also help you locate the full text or PDF link for the article or figures/tables referenced.